Get the Stockscreener App
4.62
4.05%
0.18
After Hours:
4.22
-0.40
-8.66%
Dogwood Therapeutics Inc stock is traded at $4.62, with a volume of 29,291.
It is up +4.05% in the last 24 hours and up +0.00% over the past month.
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
See More
Previous Close:
$4.44
Open:
$4.3
24h Volume:
29,291
Relative Volume:
0.77
Market Cap:
$6.16M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+3.59%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$4.19
$4.72
1-Week Range:
$4.05
$4.72
52-Week Range:
$2.80
$5.29
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Dogwood Therapeutics Inc Stock (DWTX) Latest News
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Marketscreener.com
Dogwood Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
Dogwood Therapeutics regains Nasdaq compliance - Investing.com
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia - Marketscreener.com
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
Dogwood Therapeutics : Corporate Presentation (Virios DWTX Inc. Corporate Overview Q4 2024) - Marketscreener.com
Dogwood Therapeutics, Inc. Expected to Earn Q3 2024 Earnings of ($1.40) Per Share (NASDAQ:DWTX) - Defense World
Dogwood Therapeutics, Inc.DWTX: Virios Therapeutics Becomes Dogwood Therapeutics - Smartkarma
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
Financial Metrics Check: Dogwood Therapeutics Inc. (DWTX)’s Ratios for Trailing Twelve Months - The Dwinnex
VIRIOS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Dogwood Therapeutics (DWTX) Stock Chart and Price History 2024 - MarketBeat
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 - Marketscreener.com
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - Marketscreener.com
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 - Marketscreener.com
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Marketscreener.com
United States shares higher at close of trade; Dow Jones Industrial Average up 1.03% - Investing.com India
Virios Therapeutics shares target raised on Wex merger news - Investing.com
New obesity treatment has this tiny co soaring 💃 - RagingBull
Virios Therapeutics Transforms into Dogwood Therapeutics - Yahoo Finance
CKLIFE SCIENCES Hopes to Introduce Investors for Newly Merged Dogwood (DWTX.US) - AASTOCKS.com
Virios Therapeutics announces strategic merger and financing - Investing.com
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. to Combine to Form Dogwood Therapeutics, Inc. - Orrick
Virios Therapeutics And Wex Pharmaceuticals To Merge - citybiz
VIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to Shareholders - Marketscreener.com
Virios Therapeutics, Wex Pharmaceuticals announce business combination agreement - TipRanks
Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics - MSN
Virios Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Conjoint Inc. Enters into the Loan Agreement with the Virios Therapeutics, Inc - Marketscreener.com
Virios Therapeutics announces strategic merger and financing By Investing.com - Investing.com UK
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) - Yahoo Finance
Virios Therapeutics Announces Second Quarter 2024 Financial Results - Marketscreener.com
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - Marketscreener.com
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - Marketscreener.com
Capital Bancorp (CBNK) to Buy Integrated Financial for $66M - Yahoo Finance
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results - Marketscreener.com
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Marketscreener.com
Virios Therapeutics, Inc. Announces Termination of At-The-Market Sales Agreement - Marketscreener.com
Virios Therapeutics CEO Greg Duncan to Present at the SHARE Series Investor Event on Monday, September 18, 2023 - Marketscreener.com
Virios Therapeutics Announces Halt to At-The-Market Offering Sales - Marketscreener.com
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Marketscreener.com
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study - Marketscreener.com
Virios Therapeutics : Letter from Nasdaq, dated May 24, 2023 (furnished herewith)Form 8-K - Marketscreener.com
VIRIOS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
VIRIOS THERAPEUTICS, INC. : Other Events (form 8-K) - Marketscreener.com
VIRIOS THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K) - Marketscreener.com
Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023 - Marketscreener.com
Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program - Marketscreener.com
Transcript : Virios Therapeutics, Inc., Q3 2022 Earnings Call, Nov 14, 2022 - Marketscreener.com
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
There is no financial data for Dogwood Therapeutics Inc (DWTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):